# A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation

> **NCT05049850** · PHASE2 · TERMINATED · sponsor: **Hansa Biopharma AB** · enrollment: 3 (actual)

## Conditions studied

- Kidney Transplantation in Highly Sensitized Patients

## Interventions

- **DRUG:** Imlifidase

## Key facts

- **NCT ID:** NCT05049850
- **Lead sponsor:** Hansa Biopharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-16
- **Primary completion:** 2024-02-05
- **Final completion:** 2024-05-08
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Company decision, not due to any safety reason
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05049850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05049850, "A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05049850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*